A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma.

Trial Profile

A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs MK 0752 (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Lymphoma; Myelodysplastic syndromes; Myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Jan 2010 Official Title amended, planned number of patients changed from 36 to 50 as reported by ClinicalTrials.gov.
    • 08 Feb 2008 Status change from in progress to discontinued.
    • 03 Nov 2006 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top